Abstract：
Aim: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity. Methods: PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI). Results: 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); p = 0.005; I2= 32%], HF hospitalization [RR = 0.20 (0.04-1.02); p = 0.05; I2= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); p = 0.11, I2= 0%]. Conclusion: SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient\'s chances of survival by undergoing anthracycline treatment.
What is this article about? This article explores the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a solution for reducing anthracycline-induced cardiotoxicity. Anthracycline is an established subclass of chemotherapeutic drugs which has been known to cause harm to the heart. The study, conducted a systematic search of PubMed and Google Scholar up until September 2023, assessing the effects of SGLT2i on overall mortality and cardiovascular events in cancer patients, regardless of the presence or absence of diabetes mellitus and the effectiveness of SGLT2i as a cardiotoxic therapy in cancer patients.What were the results? The analysis of studies involving 2817 patients showed findings indicating that giving SGLT2i could lower the chances of anthracycline-induced heart problems in cancer patients undergoing treatment. The findings showed a striking decrease in hospitalization due to heart failure and overall mortality whereas the findings for the effect of SGLT2i on incidence of heart failure were insignificant. The encouraging outcomes offer valuable insights that could help enhance the outlook and chances of survival for individuals with cancer.What do the results of the study mean? These findings indicate that SGLT2i notably reduces the risk of death and cardiovascular issues, like being hospitalized due to heart failure, in cancer patients undergoing anthracycline treatment. This has significant implications for how doctors might treat cancer patients in practice. Including SGLT2i in the treatment plan could improve the survival prospects of these patients, offering a promising advancement in handling anthracycline-induced heart issues with side effects that can be managed.
What is this article about? This article explores the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a solution for reducing anthracycline-induced cardiotoxicity. Anthracycline is an established subclass of chemotherapeutic drugs which has been known to cause harm to the heart. The study, conducted a systematic search of PubMed and Google Scholar up until September 2023, assessing the effects of SGLT2i on overall mortality and cardiovascular events in cancer patients, regardless of the presence or absence of diabetes mellitus and the effectiveness of SGLT2i as a cardiotoxic therapy in cancer patients.What were the results? The analysis of studies involving 2817 patients showed findings indicating that giving SGLT2i could lower the chances of anthracycline-induced heart problems in cancer patients undergoing treatment. The findings showed a striking decrease in hospitalization due to heart failure and overall mortality whereas the findings for the effect of SGLT2i on incidence of heart failure were insignificant. The encouraging outcomes offer valuable insights that could help enhance the outlook and chances of survival for individuals with cancer.What do the results of the study mean? These findings indicate that SGLT2i notably reduces the risk of death and cardiovascular issues, like being hospitalized due to heart failure, in cancer patients undergoing anthracycline treatment. This has significant implications for how doctors might treat cancer patients in practice. Including SGLT2i in the treatment plan could improve the survival prospects of these patients, offering a promising advancement in handling anthracycline-induced heart issues with side effects that can be managed.
摘要：
目的：钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）降低蒽环类药物诱导的心脏毒性。方法：直到2023年9月，PubMed和GoogleScholar一直搜索有关SGLT2i治疗蒽环类药物引起的心脏毒性的研究。考虑了总死亡率和心血管事件。使用随机效应模型，数据汇集了95%置信区间(CI)的RR和HR。结果：确定了3项队列研究，分析2817名患者。结果显示总死亡率显著降低[RR=0.52(0.33-0.82);p=0.005;I2=32%]。HF住院率[RR=0.20(0.04-1.02);p=0.05;I2=0%]且HF发生率无显著降低[RR=0.50(0.20-1.16);p=0.11,I2=0%]。结论：SGLT2i可降低因心力衰竭导致的死亡率和住院率，通过蒽环类药物治疗提高癌症患者的生存机会。
本文是关于什么的？本文探讨了钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）作为减少蒽环类抗生素诱导的心脏毒性的解决方案的用途。蒽环类是已确定的化疗药物亚类，已知会对心脏造成伤害。这项研究,截至2023年9月，对PubMed和GoogleScholar进行了系统搜索，评估SGLT2i对癌症患者总死亡率和心血管事件的影响，无论是否存在糖尿病以及SGLT2i作为癌症患者的心脏毒性疗法的有效性。结果是什么？对涉及2817名患者的研究的分析表明，给予SGLT2i可以降低接受治疗的癌症患者蒽环类药物引起的心脏病的机会。研究结果表明，由于心力衰竭和总死亡率导致的住院率显着下降，而SGLT2i对心力衰竭发生率的影响则微不足道。令人鼓舞的结果提供了有价值的见解，可以帮助提高癌症患者的前景和生存机会。这项研究的结果意味着什么？这些发现表明SGLT2i显著降低了死亡和心血管疾病的风险，比如因心力衰竭住院，在接受蒽环类药物治疗的癌症患者中。这对医生在实践中如何治疗癌症患者具有重要意义。将SGLT2i纳入治疗计划可以改善这些患者的生存前景，在处理蒽环类药物引起的心脏问题方面提供了有希望的进展，副作用可以控制。
本文是关于什么的？本文探讨了钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）作为减少蒽环类抗生素诱导的心脏毒性的解决方案的用途。蒽环类是已确定的化疗药物亚类，已知会对心脏造成伤害。这项研究,截至2023年9月，对PubMed和GoogleScholar进行了系统搜索，评估SGLT2i对癌症患者总死亡率和心血管事件的影响，无论是否存在糖尿病以及SGLT2i作为癌症患者的心脏毒性疗法的有效性。结果是什么？对涉及2817名患者的研究的分析表明，给予SGLT2i可以降低接受治疗的癌症患者蒽环类药物引起的心脏病的机会。研究结果表明，由于心力衰竭和总死亡率导致的住院率显着下降，而SGLT2i对心力衰竭发生率的影响则微不足道。令人鼓舞的结果提供了有价值的见解，可以帮助提高癌症患者的前景和生存机会。这项研究的结果意味着什么？这些发现表明SGLT2i显著降低了死亡和心血管疾病的风险，比如因心力衰竭住院，在接受蒽环类药物治疗的癌症患者中。这对医生在实践中如何治疗癌症患者具有重要意义。将SGLT2i纳入治疗计划可以改善这些患者的生存前景，在处理蒽环类药物引起的心脏问题方面提供了有希望的进展，副作用可以控制。
